Thrombolysis for acute ischaemic stroke: current status and future perspectives
Alteplase is currently the only approved thrombolytic agent for treatment of acute ischaemic
stroke, but interest is burgeoning in the development of new thrombolytic agents for systemic …
stroke, but interest is burgeoning in the development of new thrombolytic agents for systemic …
[HTML][HTML] The multifaceted role of plasminogen in inflammation
A fine-tuned activation and deactivation of proteases and their inhibitors are involved in the
execution of the inflammatory response. The zymogen/proenzyme plasminogen is converted …
execution of the inflammatory response. The zymogen/proenzyme plasminogen is converted …
[HTML][HTML] Fibrinolysis: an illustrated review
In response to vessel injury (or other pathological conditions), the hemostatic process is
activated, resulting in a fibrous, cellular-rich structure commonly referred to as a blood clot …
activated, resulting in a fibrous, cellular-rich structure commonly referred to as a blood clot …
Fibrin matrices as (injectable) biomaterials: formation, clinical use, and molecular engineering
IV Roberts, D Bukhary… - Macromolecular …, 2020 - Wiley Online Library
This review focuses on fibrin, starting from biological mechanisms (its production from
fibrinogen and its enzymatic degradation), through its use as a medical device and as a …
fibrinogen and its enzymatic degradation), through its use as a medical device and as a …
Thrombolytic enzymes of microbial origin: a review
D Diwan, Z Usmani, M Sharma, JW Nelson… - International journal of …, 2021 - mdpi.com
Enzyme therapies are attracting significant attention as thrombolytic drugs during the current
scenario owing to their great affinity, specificity, catalytic activity, and stability. Among various …
scenario owing to their great affinity, specificity, catalytic activity, and stability. Among various …
Fucoidan-functionalized polysaccharide submicroparticles loaded with alteplase for efficient targeted thrombolytic therapy
A Zenych, C Jacqmarcq, R Aid, L Fournier… - Biomaterials, 2021 - Elsevier
Intravenous administration of fibrinolytic drugs is the standard treatment of acute thrombotic
diseases. However, current fibrinolytics exhibit limited clinical efficacy because of their short …
diseases. However, current fibrinolytics exhibit limited clinical efficacy because of their short …
Use of exogenous enzymes in human therapy: approved drugs and potential applications
P Cioni, E Gabellieri, B Campanini… - Current Medicinal …, 2022 - ingentaconnect.com
The development of safe and efficacious enzyme-based human therapies has increased
greatly in the last decades, thanks to remarkable advances in the understanding of the …
greatly in the last decades, thanks to remarkable advances in the understanding of the …
The recent applications of plga-based nanostructures for ischemic stroke
J Yan, L Huang, J Feng, X Yang - Pharmaceutics, 2023 - mdpi.com
With the accelerated development of nanotechnology in recent years, nanomaterials have
become increasingly prevalent in the medical field. The poly (lactic acid–glycolic acid) …
become increasingly prevalent in the medical field. The poly (lactic acid–glycolic acid) …
Impact of SMTP targeting plasminogen and soluble epoxide hydrolase on thrombolysis, inflammation, and ischemic stroke
K Hasumi, E Suzuki - International Journal of Molecular Sciences, 2021 - mdpi.com
Stachybotrys microspora triprenyl phenol (SMTP) is a large family of small molecules
derived from the fungus S. microspora. SMTP acts as a zymogen modulator (specifically …
derived from the fungus S. microspora. SMTP acts as a zymogen modulator (specifically …
New approaches in nanomedicine for ischemic stroke
C Correa-Paz, A da Silva-Candal, E Polo, J Parcq… - Pharmaceutics, 2021 - mdpi.com
Ischemic stroke, caused by the interruption of blood flow to the brain and subsequent
neuronal death, represents one of the main causes of disability in developed countries …
neuronal death, represents one of the main causes of disability in developed countries …